A Single Dose Study to Assess the Pharmacokinetics of SCH 900800 Administered as Oral Tablets in L-DOPA-treated Subjects With Parkinson's Disease.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 23 Dec 2014
At a glance
- Drugs MK 8800 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 01 Jul 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 21 Jun 2012 Planned End Date changed from 1 Dec 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
- 21 Jun 2012 Planned initiation date changed from 1 Jun 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov record.